3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
2
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
196
Nivolumab
145
Carboplatin
134
Specimen Handling
130
Magnetic Resonance Spectroscopy
115
Cyclophosphamide
109
Paclitaxel
106
Cisplatin
98
Biopsy
97
Radiotherapy
90
durvalumab
81
Dexamethasone
79
atezolizumab
73
Ipilimumab
62
Gemcitabine
62
Rituximab
59
Doxorubicin
59
Lenalidomide
55
Docetaxel
55
olaparib
53
Bevacizumab
51
Capecitabine
50
Fluorouracil
49
Etoposide
49
Radiation
47
Oxaliplatin
47
Radiosurgery
43
venetoclax
42
Prednisone
42
Taxes
41
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Active not recruiting
×
budigalimab
×
Clear all
NCT05822752
2025-08-14
LIVIGNO-1
AbbVie
Phase 2
Active not recruiting
130 enrolled
NCT06632951
2025-08-11
LIVIGNO-3
AbbVie
Phase 2
Active not recruiting
150 enrolled